PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) saw a large growth in short interest in March. As of March 13th, there was short interest totaling 1,485,129 shares, a growth of 20.5% from the February 26th total of 1,232,783 shares. Approximately 3.0% of the company’s shares are short sold. Based on an average trading volume of 1,544,359 shares, the days-to-cover ratio is presently 1.0 days.

PMV Pharmaceuticals Price Performance

Shares of PMV Pharmaceuticals stock opened at $1.33 on Thursday. PMV Pharmaceuticals has a one year low of $0.81 and a one year high of $1.88. The firm has a market capitalization of $70.93 million, a price-to-earnings ratio of -0.89 and a beta of 1.40. The business has a 50-day simple moving average of $1.30 and a 200 day simple moving average of $1.31.

PMV Pharmaceuticals (NASDAQ:PMVP) last announced its quarterly earnings results on Friday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06. On average, sell-side analysts expect that PMV Pharmaceuticals will post -1.06 EPS for the current year.

Institutional Trading of PMV Pharmaceuticals

Several hedge funds have recently bought and sold shares of PMVP. Shay Capital LLC bought a new stake in PMV Pharmaceuticals during the 2nd quarter valued at $26,000. Squarepoint Ops LLC lifted its stake in shares of PMV Pharmaceuticals by 101.8% in the fourth quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock valued at $33,000 after buying an additional 13,367 shares in the last quarter. Public Employees Retirement System of Ohio lifted its stake in shares of PMV Pharmaceuticals by 349.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock valued at $34,000 after buying an additional 21,334 shares in the last quarter. Algert Global LLC acquired a new position in shares of PMV Pharmaceuticals during the third quarter valued at about $87,000. Finally, Seven Fleet Capital Management LP acquired a new position in shares of PMV Pharmaceuticals during the fourth quarter valued at about $79,000. Institutional investors and hedge funds own 90.20% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of PMV Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.